OPEN APP
Home >Companies >Novartis launches anti-psoriasis drug Scapho in India
A file photo of the Novartis India headquarters in Mumbai. Photo: Reuters
A file photo of the Novartis India headquarters in Mumbai. Photo: Reuters

Novartis launches anti-psoriasis drug Scapho in India

Secukinumab was developed for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy

Hyderabad: Novartis Healthcare Pvt. Ltd (NHPL), a unit of Swiss multinational pharmaceutical company Novartis International AG on Thursday said it has launched a drug, Scapho 150 mg, in India for the treatment of psoriasis.

Scapho, generically called as secukinumab, is an injectable medicine and the first interleukin-17A (IL-17A) inhibitor to be approved in India for the treatment of moderate-to-severe plaque psoriasis in adult patients.

Novartis didn’t disclose the pricing of the drug.

Scapho branded as Cosentyx in the US and Europe is a fully human monoclonal antibody that selectively neutralizes circulating IL-17A.

Research suggests that IL-17A may play an important role in driving the body’s immune response in psoriasis, psoriatic arthritis and ankylosing spondylitis

“This approval marks a significant milestone in the treatment of psoriasis, providing a new and important first-line biologic treatment option for patients who are candidates for systemic therapy, Novartis said in a statement.

Secukinumab was developed for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy with a recommended dose of 300 mg.

“This is groundbreaking news as clear skin can now be a reality for patients struggling to cope with psoriasis," said Anchala Parthasaradhi, senior dermatologist and director of Anchala Skin Institute, Hyderabad.

Psoriasis is a common, non-contagious, autoimmune disease that affects up to 3% of the world’s population.

Plaque psoriasis is the most common form of the disease and appears as raised, red patches covered with a silvery white buildup of dead skin cells.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My Reads Redeem a Gift Card Logout